<div id="readability-page-1"><p>TRex Bio, Inc. announced that it has received $50 million in a round of funding on January 27, 2026.The transaction included participation from new investors Janus Henderson Investors US LLC, Balyasny Asset Management L.P., Affinity Asset Advisors, LLC, returning investors Alexandria Venture Investments, LLC, Delos Advisors Limited, Eli Lilly and Company (NYSE:LLY), Johnson &amp; Johnson Innovation - JJDC, Inc., Pfizer Venture Investments LLC, Polaris Venture Partners, Inc., SV Health Investors, LLC, Avego BioScience Capital. The company issued convertible preferred shares in the transaction.</p></div>

<p>TRex Bio, Inc. announced it has secured $50 million in funding on January 27, 2026. The funding round saw participation from both new and returning investors, including Janus Henderson Investors, Balyasny Asset Management, and Eli Lilly. The company issued convertible preferred shares as part of the transaction.</p>

marketscreener

Defiance Daily Target 2X Long LLY ETF

Ark Genomic Revolution ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Eli Lilly

Invesco Biotechnology & Genome ETF

VG Health

Invesco Nasdaq Biotechnology ETF

PROMETHEUS BIOSCIENCES INC

iShares US Pharma

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Health Care Select Sector SPDR

TRex Bio, Inc. announced that it has received $50 million in funding from a group of investors